Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Coverage across specialized and mainstream publications emphasizes that the experimental oral medication met its main goals in late-stage studies by significantly reducing relapse rates and outperforming an approved older therapy in two large trials. Outlets such as Fierce Pharma and Multiple Sclerosis News Today highlight that the Phase 3 trials showed no liver safety signal, with Endpoints News and other sources noting that the data suggest the pill is safer than rivals. Additional reporting from Yahoo Finance and other financial platforms details how TGTX stock pared opening losses after an analyst dismissed competition from Novartis, while Investor's Business Daily notes a six percent surge in Novartis stock and Bloomberg discusses boosted blockbuster prospects for the company's drug pipeline.
Background context within the coverage establishes that these late-stage trials specifically targeted relapsing multiple sclerosis, positioning the BTK inhibitor to compete directly in a major therapeutic market. BioSpace explicitly connects these positive Phase 3 results to an impending commercial and clinical battle with Roche. The company itself characterized the drug in its announcements as a high-efficacy oral BTK inhibitor that not only clears major Phase III hurdles in relapsing MS but also presents a favorable safety profile compared to existing therapeutic options currently available to patients suffering from the condition.
Looking ahead based strictly on the provided headlines, financial analysts and market observers will be tracking the ongoing performance of Novartis stock, potential breakout patterns noted by Investor's Business Daily, and the competitive positioning of TGTX against Novartis. Coverage does not yet specify the precise dates for regulatory submissions or commercial rollouts, leaving the immediate next steps in the hands of regulatory bodies and upcoming corporate disclosures from the pharmaceutical manufacturer concerning Rhapsido and remibrutinib.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (80% supported) Updated 74d ago.
Quick answers
What drug is responsible for the Novartis stock surge?
Coverage identifies the drug as Rhapsido, also known as remibrutinib, an oral BTK inhibitor.
Which outlets covered the Phase III trial results?
Numerous outlets reported on the trials, including The Wall Street Journal, Bloomberg, Reuters, Yahoo Finance, BioSpace, and Fierce Pharma.
What condition were the late-stage trials evaluating?
The trials evaluated the drug for treating relapsing multiple sclerosis.
Coverage (19)
- Novartis (SWX:NOVN) Reports Two Positive Phase III Results For Oral MS Drug Yahoo Finance · 77d ago
- Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials tipranks.com · 77d ago
- TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis finance.yahoo.com · 77d ago
- Novartis BTK inhibitor clears Phase III hurdle in relapsing MS The Pharma Letter · 77d ago
- Experimental oral MS drug outperforms approved therapy in 2 trials Multiple Sclerosis News Today · 77d ago
- Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle BioSpace · 77d ago
- Novartis claims MS win as Rhapsido clears phase 3 with ‘no liver safety signal’ Fierce Pharma · 77d ago
- Novartis' Rhapsido delivers dual Phase III wins in relapsing MS FirstWord Pharma · 77d ago
- Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials Novartis · 77d ago
- Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping Investopedia · 77d ago
- Novartis sets sights on new oral MS drug after phase 3 wins pharmaphorum · 77d ago
- Novartis' oral multiple sclerosis drug meets main goal in late stage studies Yahoo Finance · 77d ago
- Novartis’ Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest Endpoints News · 77d ago
- Novartis says MS pill succeeds in two large studies BioPharma Dive · 77d ago
- Why Novartis Just Surged 6%, Eyeing A Breakout Investor's Business Daily · 77d ago
- Novartis’ MS Pill Trial Success Boosts Blockbuster Prospects Bloomberg.com · 77d ago
- Novartis remibrutinib, a high-efficacy oral BTK inhibitor, GlobeNewswire · 77d ago
- Novartis MS pill beats older drug in trials, boosts pipeline hopes Reuters · 77d ago
- Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials WSJ · 77d ago
Topics
Related trends
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
Christina Applegate reveals surprising theory about what caused misdiagnosed MS symptoms
Christina Applegate says she suspects her breast implants may be causing the symptoms that led to a 2021 multiple sclerosis diagnosis, which a doctor recently told her was incorrect.
Former Fox host suffers severe health upset after MS diagnosis: ‘It could take months to recover’
Former Fox News meteorologist Janice Dean, 56, reveals she has been diagnosed with viral meningitis months after retiring due to multiple sclerosis, saying recovery could take months.
Toukie Smith Dead: '227' Actor & Former Partner Of Robert De Niro Was 74
Model and actress Toukie Smith, known for her role on the NBC sitcom '227' and as the former partner of Robert De Niro, died on November 4 at age 74 after a long battle with multiple sclerosis.
Toukie Smith, Top Runway Model and ‘227’ Actress, Dies at 74
Toukie Smith, runway model and 227 actress, died at 74 after a long battle with multiple sclerosis.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.